Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition for treating vitreous opacity and preparation method of drug composition

A vitreous opacity and composition technology, which is applied in the directions of drug combinations, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the vitreous hyperplasia caused by factors such as cell or inflammatory cell decomposition products, fibrin, and fibroblast proliferation. Sexual changes, difficult recovery of visual function, decreased vision, etc.

Inactive Publication Date: 2017-05-24
JINAN HAOYU QINGTIAN PHARMA TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If not treated in time, hemorrhage or inflammatory substances may be absorbed delayed, or even not absorbed for a long time, not only cause vision loss, but also cause vitreous hyperplasia due to factors such as red blood cells or inflammatory cell decomposition products, fibrin, and fibroblast proliferation in the vitreous Sexual changes, angiogenesis, hemosiderosis, and some serious complications such as neovascular glaucoma and traction retinal detachment may occur, making it more difficult to restore visual function

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1: the pharmaceutical composition and preparation method thereof for the treatment of vitreous opacity

[0036] The composition and parts by weight of the raw material drug of the pharmaceutical composition for treating vitreous opacity are: 565g of Prolactinus 565g, 503g of Phytophthora falciparum, 206g of Achyrantheron 206g, 55g of Utura japonica, 13g of Burnet saponin II;

[0037] Preparation:

[0038] (1) According to the ratio of raw materials, take prolactin vine, sarcophagus spp., achyrantheterone, twig vine, and burnet saponin II, mix well, use 30% ethanol as a solvent, and extract by warm soaking at 25.5°C , the number of extractions is 7 times, each extraction time is 36 hours, and the amount of solvent used each time is 45 times the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, extract A reclaims ethanol, and concentrates to a relative density of 1.13 , filtered, the liquid medicine passes through the...

Embodiment 2

[0041] Embodiment 2: the pharmaceutical composition and preparation method thereof for the treatment of vitreous opacity

[0042] The composition and parts by weight of the raw material drug of the pharmaceutical composition for treating vitreous opacity are: 562g of Prolactinus 562g, 506g of Phytophthora falciparum, 204g of Achyranthene 60g, 12g of Saponin II;

[0043] Preparation:

[0044] (1) According to the ratio of raw materials, take prolactin vine, sarcophagus spp., achyrantheterone, twig vine, and burnet saponin II, mix well, use 30% ethanol as a solvent, and extract by warm soaking at 25.5°C , the number of extractions is 7 times, each extraction time is 36 hours, and the amount of solvent used each time is 45 times the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, extract A reclaims ethanol, and concentrates to a relative density of 1.13 , filtered, the liquid medicine passes through the HP40 macroporous adsorption res...

Embodiment 3

[0047] Embodiment 3: the pharmaceutical composition and preparation method thereof for the treatment of vitreous opacity

[0048] The composition and parts by weight of the raw material drug of the pharmaceutical composition for treating vitreous opacity are: 568g of Prolactinus 568g, 500g of Phytophthora falciparum, 208g of Achyranthene 50g, 14g of Burnet saponin II;

[0049] Preparation:

[0050] (1) According to the ratio of raw materials, take prolactin vine, sarcophagus spp., achyrantheterone, twig vine, and burnet saponin II, mix well, use 30% ethanol as a solvent, and extract by warm soaking at 25.5°C , the number of extractions is 7 times, each extraction time is 36 hours, and the amount of solvent used each time is 45 times the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, extract A reclaims ethanol, and concentrates to a relative density of 1.13 , filtered, the liquid medicine passes through the HP40 macroporous adsorpt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composition for treating vitreous opacity and a preparation method of the drug composition. The drug composition is prepared by taking heterostemma oblongifolium cost, calanthe puberula, inokosterone, entada phaseoloides and ziyuglycoside II as active pharmaceutical ingredients, and mixing the active pharmaceutical ingredients according to a proportion. The drug composition can be prepared into various dosage forms according to the conventional preparation technology and has significant therapy efficacy for treating the vitreous opacity.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition for treating vitreous opacity and a preparation method thereof. Background technique [0002] The vitreous body is a transparent jelly-like tissue, the main component is a network frame composed of collagen fibers, which is filled with hyaluronic acid adsorbing molecules, and the field of vision is clear and flawless, ensuring the acuity of vision. Once an opaque body other than the normal structure appears in the vitreous, it can cause vitreous opacity. Vitreous opacity is a common eye disease in ophthalmology. Vitreous opacity is mostly caused by hemorrhage (ocular trauma, diabetes, hypertension, retinal periphlebitis, rhegmatogenous retinal detachment, etc.), inflammation (uveitis, endophthalmitis, etc.) and degeneration (such as medium to high myopia) and many other reasons cause. If not treated in time, hemorrh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/898A61P27/02A61K31/704A61K31/56
CPCA61K36/48A61K31/56A61K31/704A61K36/27A61K36/898A61K2236/333A61K2236/39A61K2236/55
Inventor 不公告发明人
Owner JINAN HAOYU QINGTIAN PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com